TP53 and colorectal carcinoma: Conversely, TP53 pathway alterations were consistently high in both early‐onset (89.1%) and late‐onset (81.7%) Hispanic/Latino patients (p = 0.1), reflecting the pathway's critical and widespread role in CRC regardless of age at diagnosis.